Replimune Group (NASDAQ:REPL) PT Lowered to $14.00 at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) had its price target reduced by JPMorgan Chase & Co. from $17.00 to $14.00 in a report issued on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

REPL has been the subject of several other reports. Wedbush restated an outperform rating and set a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. Barclays boosted their price target on Replimune Group from $13.00 to $17.00 and gave the company an overweight rating in a report on Friday, June 7th. Finally, HC Wainwright boosted their price target on Replimune Group from $12.00 to $17.00 and gave the company a buy rating in a report on Friday, June 7th.

Replimune Group Price Performance

Shares of REPL stock traded down $0.11 during midday trading on Tuesday, reaching $10.19. 67,650 shares of the company traded hands, compared to its average volume of 1,191,624. The firm’s 50 day simple moving average is $9.30 and its two-hundred day simple moving average is $7.97. Replimune Group has a 1-year low of $4.92 and a 1-year high of $21.32. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.72 and a quick ratio of 10.72. The firm has a market cap of $696.18 million, a PE ratio of -3.14 and a beta of 1.25.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. On average, equities research analysts expect that Replimune Group will post -3.31 EPS for the current fiscal year.

Insider Activity

In related news, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $7.50, for a total transaction of $119,107.50. Following the completion of the sale, the insider now directly owns 117,131 shares of the company’s stock, valued at approximately $878,482.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its position in Replimune Group by 236.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after buying an additional 2,958 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group in the 2nd quarter valued at about $57,000. Quest Partners LLC acquired a new stake in shares of Replimune Group in the 4th quarter valued at about $76,000. Finally, Diversified Trust Co acquired a new stake in shares of Replimune Group in the 1st quarter valued at about $94,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.